KR20070116936A - 혈전증의 치료를 위한 신규 약제학적 조성물 - Google Patents
혈전증의 치료를 위한 신규 약제학적 조성물 Download PDFInfo
- Publication number
- KR20070116936A KR20070116936A KR1020077024953A KR20077024953A KR20070116936A KR 20070116936 A KR20070116936 A KR 20070116936A KR 1020077024953 A KR1020077024953 A KR 1020077024953A KR 20077024953 A KR20077024953 A KR 20077024953A KR 20070116936 A KR20070116936 A KR 20070116936A
- Authority
- KR
- South Korea
- Prior art keywords
- chloro
- carbonyl
- pharmaceutical composition
- benzimidazol
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 66
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 39
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 37
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims abstract description 30
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 19
- 239000003937 drug carrier Substances 0.000 claims abstract description 16
- 239000002319 fibrinogen receptor antagonist Substances 0.000 claims abstract description 14
- 229920000669 heparin Polymers 0.000 claims abstract description 14
- 229940127215 low-molecular weight heparin Drugs 0.000 claims abstract description 14
- 229940019333 vitamin k antagonists Drugs 0.000 claims abstract description 14
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 13
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 13
- 239000005557 antagonist Substances 0.000 claims abstract description 13
- 108090000190 Thrombin Proteins 0.000 claims abstract description 11
- 229940122388 Thrombin inhibitor Drugs 0.000 claims abstract description 10
- 229920001499 Heparinoid Polymers 0.000 claims abstract description 8
- 239000002554 heparinoid Substances 0.000 claims abstract description 8
- 229940025770 heparinoids Drugs 0.000 claims abstract description 5
- -1 4-amidinophenylaminomethyl Chemical group 0.000 claims description 69
- 150000003839 salts Chemical class 0.000 claims description 63
- 239000000203 mixture Substances 0.000 claims description 51
- 239000003112 inhibitor Substances 0.000 claims description 34
- 238000009472 formulation Methods 0.000 claims description 29
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 21
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 21
- 108010014173 Factor X Proteins 0.000 claims description 18
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 17
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 17
- 229960003009 clopidogrel Drugs 0.000 claims description 16
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical group C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 14
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 13
- 239000003055 low molecular weight heparin Substances 0.000 claims description 12
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 12
- 229940125782 compound 2 Drugs 0.000 claims description 10
- 150000004677 hydrates Chemical class 0.000 claims description 10
- 229960004072 thrombin Drugs 0.000 claims description 10
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 9
- 206010047249 Venous thrombosis Diseases 0.000 claims description 9
- 208000010125 myocardial infarction Diseases 0.000 claims description 9
- 239000003146 anticoagulant agent Substances 0.000 claims description 8
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 229960005001 ticlopidine Drugs 0.000 claims description 7
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 7
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 6
- 239000003698 antivitamin K Substances 0.000 claims description 6
- 238000002513 implantation Methods 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 230000002537 thrombolytic effect Effects 0.000 claims description 6
- 230000001732 thrombotic effect Effects 0.000 claims description 6
- 208000001435 Thromboembolism Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 229960002137 melagatran Drugs 0.000 claims description 3
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 3
- 230000000399 orthopedic effect Effects 0.000 claims description 3
- 230000009861 stroke prevention Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims description 2
- 102000007625 Hirudins Human genes 0.000 claims description 2
- 108010007267 Hirudins Proteins 0.000 claims description 2
- 229960003850 dabigatran Drugs 0.000 claims description 2
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 2
- 229940006607 hirudin Drugs 0.000 claims description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 2
- 229950003291 inogatran Drugs 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- SEGHHPAKTYKSLB-UHFFFAOYSA-N ethyl 3-[[2-[[4-[(hexoxycarbonylhydrazinylidene)methyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate Chemical compound C1=CC(C=NNC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C SEGHHPAKTYKSLB-UHFFFAOYSA-N 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 abstract description 4
- 229940123583 Factor Xa inhibitor Drugs 0.000 abstract 2
- 239000013543 active substance Substances 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 15
- 229940125904 compound 1 Drugs 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 7
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 229940098779 methanesulfonic acid Drugs 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000011976 maleic acid Chemical class 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000001530 fumaric acid Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 4
- 239000011975 tartaric acid Substances 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 3
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 3
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 150000001447 alkali salts Chemical class 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229960000610 enoxaparin Drugs 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Chemical class 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 description 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Chemical class 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- XGBHUMKSNKSZNX-AWEZNQCLSA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]-6-methylquinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2C)=NC=NC1=CC=2C(=O)N1CCCC1 XGBHUMKSNKSZNX-AWEZNQCLSA-N 0.000 description 2
- RQHGXOYKVGDQRP-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 RQHGXOYKVGDQRP-IBGZPJMESA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 229960003886 apixaban Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960004969 dalteparin Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- VYNKVNDKAOGAAQ-RUZDIDTESA-N n-[(1r)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1h-indole-6-carboxamide Chemical compound C1CN(C)CCC1N1CCN(C(=O)[C@H](NC(=O)C=2C=C3NC=CC3=CC=2)C=2C=CC=CC=2)CC1 VYNKVNDKAOGAAQ-RUZDIDTESA-N 0.000 description 2
- RUHMXJKQXZYSIF-UHFFFAOYSA-N n-[(6-chloro-1h-benzimidazol-2-yl)-phenylmethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)NC(C=2NC3=CC=C(Cl)C=C3N=2)C=2C=CC=CC=2)=CC=C1C(=O)N1CCCC1 RUHMXJKQXZYSIF-UHFFFAOYSA-N 0.000 description 2
- 229960000899 nadroparin Drugs 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960005062 tinzaparin Drugs 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- DEJXXVQJMXTPLQ-SFHVURJKSA-N (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoic acid Chemical compound N([C@@H](CCC(=O)O)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 DEJXXVQJMXTPLQ-SFHVURJKSA-N 0.000 description 1
- OHHAYGMJNFSKNG-LIRRHRJNSA-N (4s)-4-[[7-[(2s)-2-(aminomethyl)pyrrolidine-1-carbonyl]-6-chloroquinazolin-4-yl]amino]-4-(6-chloro-1h-benzimidazol-2-yl)butanoic acid Chemical compound NC[C@@H]1CCCN1C(=O)C1=CC2=NC=NC(N[C@@H](CCC(O)=O)C=3NC4=CC=C(Cl)C=C4N=3)=C2C=C1Cl OHHAYGMJNFSKNG-LIRRHRJNSA-N 0.000 description 1
- DMJDEZUEYXVYNO-DHZHZOJOSA-N (e)-3-(4-phenylphenyl)prop-2-enoic acid Chemical class C1=CC(/C=C/C(=O)O)=CC=C1C1=CC=CC=C1 DMJDEZUEYXVYNO-DHZHZOJOSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical class C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- MAOALPSHCIBFJZ-RUZDIDTESA-N 2-[[(2r)-2-[2-[[4-[amino(azaniumylidene)methyl]anilino]methyl]-1-methylbenzimidazol-5-yl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]amino]acetate Chemical compound N=1C2=CC([C@@](C)(NCC(O)=O)C(=O)N3CCCC3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 MAOALPSHCIBFJZ-RUZDIDTESA-N 0.000 description 1
- ZHXGXULYUZVCBR-UHFFFAOYSA-N 2-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazol-5-yl]-quinolin-8-ylsulfonylamino]acetic acid Chemical compound N=1C2=CC(N(CC(O)=O)S(=O)(=O)C=3C4=NC=CC=C4C=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 ZHXGXULYUZVCBR-UHFFFAOYSA-N 0.000 description 1
- UDXBFVFGUYSOME-UHFFFAOYSA-N 2-[[2-[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazol-5-yl]-2-methyl-3-oxo-3-pyrrolidin-1-ylpropyl]amino]acetic acid Chemical compound N=1C2=CC(C(C)(CNCC(O)=O)C(=O)N3CCCC3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 UDXBFVFGUYSOME-UHFFFAOYSA-N 0.000 description 1
- CXUUEHHEZJCVMT-UHFFFAOYSA-N 2-[[4-[(Z)-N'-hydroxycarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carboxylic acid Chemical compound CN1C(=NC2=C1C=CC(=C2)C(=O)O)CNC2=CC=C(C=C2)C(NO)=N CXUUEHHEZJCVMT-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- BXXAXANRYAQUAM-UHFFFAOYSA-N 2-ethyl-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound C(C)C1=C(C(=O)N)C=CC(=C1C)C(=O)N1CCCC1 BXXAXANRYAQUAM-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- UOBYKYZJUGYBDK-UHFFFAOYSA-N 2-naphthoic acid Chemical class C1=CC=CC2=CC(C(=O)O)=CC=C21 UOBYKYZJUGYBDK-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ZMPRRFPMMJQXPP-UHFFFAOYSA-N 2-sulfobenzoic acid Chemical class OC(=O)C1=CC=CC=C1S(O)(=O)=O ZMPRRFPMMJQXPP-UHFFFAOYSA-N 0.000 description 1
- GXCKBPZTXDIIHR-UHFFFAOYSA-N 3-(3-carbamimidoylphenyl)-3-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]propanoic acid Chemical compound NC(=N)C1=CC=CC(C(CC(O)=O)NC=2C3=CC(Cl)=C(C(=O)N4CCCC4)C=C3N=CN=2)=C1 GXCKBPZTXDIIHR-UHFFFAOYSA-N 0.000 description 1
- DMJDEZUEYXVYNO-UHFFFAOYSA-N 3-(4-phenylphenyl)prop-2-enoic acid Chemical compound C1=CC(C=CC(=O)O)=CC=C1C1=CC=CC=C1 DMJDEZUEYXVYNO-UHFFFAOYSA-N 0.000 description 1
- OUUHCFQNWCARFH-UHFFFAOYSA-N 3-[[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]-4-hydroxybenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(O)C(CNC=2C3=CC(Cl)=C(C(=O)N4CCCC4)C=C3N=CN=2)=C1 OUUHCFQNWCARFH-UHFFFAOYSA-N 0.000 description 1
- WUGBZNHVMYDJSZ-SFHVURJKSA-N 3-bromo-n-[(1r)-1-(6-bromo-1h-benzimidazol-2-yl)-2-hydroxyethyl]-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](CO)C=1NC2=CC=C(Br)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CCCC1 WUGBZNHVMYDJSZ-SFHVURJKSA-N 0.000 description 1
- YRGZMEPXUSMUPP-IBGZPJMESA-N 3-bromo-n-[(1r)-1-(6-bromo-1h-benzimidazol-2-yl)-2-methoxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](COC)C=1NC2=CC=C(Br)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CC=CC1 YRGZMEPXUSMUPP-IBGZPJMESA-N 0.000 description 1
- OLZCOZYOACSGTK-FQEVSTJZSA-N 3-bromo-n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-ethoxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](COCC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CC=CC1 OLZCOZYOACSGTK-FQEVSTJZSA-N 0.000 description 1
- OWCDPSYVKRORHI-IBGZPJMESA-N 3-bromo-n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CC=CC1 OWCDPSYVKRORHI-IBGZPJMESA-N 0.000 description 1
- DTXZRUBEKPVFBE-IBGZPJMESA-N 3-bromo-n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CCCC1 DTXZRUBEKPVFBE-IBGZPJMESA-N 0.000 description 1
- INEYFUQRZLZMFK-NRFANRHFSA-N 3-bromo-n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-prop-2-ynoxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](COCC#C)C=1NC2=CC=C(C=C2N=1)Cl)C(=O)C(C=C1Br)=CC=C1C(=O)N1CC=CC1 INEYFUQRZLZMFK-NRFANRHFSA-N 0.000 description 1
- SDSMXMSJNZGOBX-IBGZPJMESA-N 3-bromo-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CCCC1 SDSMXMSJNZGOBX-IBGZPJMESA-N 0.000 description 1
- DSVIZIAFVHOPPH-LPEGZLAKSA-N 3-bromo-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfinylpropyl]-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](CCS(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CCCC1 DSVIZIAFVHOPPH-LPEGZLAKSA-N 0.000 description 1
- YLPSLOPYNLABCA-IBGZPJMESA-N 3-bromo-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)butyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](CCC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CC=CC1 YLPSLOPYNLABCA-IBGZPJMESA-N 0.000 description 1
- PJHBCFOYSQUKEE-IBGZPJMESA-N 3-chloro-n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Cl)=CC=C1C(=O)N1CC=CC1 PJHBCFOYSQUKEE-IBGZPJMESA-N 0.000 description 1
- OTTTUQHZIIULLI-IBGZPJMESA-N 3-chloro-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Cl)=CC=C1C(=O)N1CCCC1 OTTTUQHZIIULLI-IBGZPJMESA-N 0.000 description 1
- AZKQDXOHILUHFD-IBGZPJMESA-N 3-chloro-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)butyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](CCC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Cl)=CC=C1C(=O)N1CC=CC1 AZKQDXOHILUHFD-IBGZPJMESA-N 0.000 description 1
- RWTQYKUONPWEES-UHFFFAOYSA-N 3-chloro-n-[(6-chloro-1h-benzimidazol-2-yl)methyl]-4-(3-oxopiperazine-1-carbonyl)benzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1CNC(=O)C(C=C1Cl)=CC=C1C(=O)N1CCNC(=O)C1 RWTQYKUONPWEES-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- UPJWBQXETHABOR-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-1-(4-hydroxypiperidin-1-yl)butan-1-one Chemical compound C1CC(O)CCN1C(=O)CCC(C=1NC2=CC=C(Cl)C=C2N=1)NC1=NC=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C12 UPJWBQXETHABOR-UHFFFAOYSA-N 0.000 description 1
- MVGLQCNJKHVLGH-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-1-(4-methylpiperazin-1-yl)butan-1-one Chemical compound C1CN(C)CCN1C(=O)CCC(C=1NC2=CC(Cl)=CC=C2N=1)NC1=NC=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C12 MVGLQCNJKHVLGH-UHFFFAOYSA-N 0.000 description 1
- KTOSDBDBNCWIKN-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-1-morpholin-4-ylbutan-1-one Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)N1CCOCC1 KTOSDBDBNCWIKN-UHFFFAOYSA-N 0.000 description 1
- GDIKJXXZRARNKX-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n,n-diethylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)N(CC)CC)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 GDIKJXXZRARNKX-UHFFFAOYSA-N 0.000 description 1
- KPCJCGWQNRDYHS-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)NCC(F)(F)F)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 KPCJCGWQNRDYHS-UHFFFAOYSA-N 0.000 description 1
- HGWPBTGFBUCYDA-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(2-hydroxyethyl)butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)NCCO)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 HGWPBTGFBUCYDA-UHFFFAOYSA-N 0.000 description 1
- TUEGSDGZOVSICV-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(2-methoxyethyl)butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)NCCOC)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 TUEGSDGZOVSICV-UHFFFAOYSA-N 0.000 description 1
- FZMLWCDQELFMQZ-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(cyclopropylmethyl)-n-methylbutanamide Chemical compound N=1C=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C2C=1NC(C=1NC2=CC=C(Cl)C=C2N=1)CCC(=O)N(C)CC1CC1 FZMLWCDQELFMQZ-UHFFFAOYSA-N 0.000 description 1
- IYKBEOXZYPPJCM-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(piperidin-4-ylmethyl)butanamide Chemical compound N1C2=CC(Cl)=CC=C2N=C1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NCC1CCNCC1 IYKBEOXZYPPJCM-UHFFFAOYSA-N 0.000 description 1
- KJAZZYOZBPUDLE-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-[2-(dimethylamino)ethyl]-n-methylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)N(C)CCN(C)C)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 KJAZZYOZBPUDLE-UHFFFAOYSA-N 0.000 description 1
- DIZXLHIFUIUOOK-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-[2-(pyridin-4-ylamino)ethyl]butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NCCNC1=CC=NC=C1 DIZXLHIFUIUOOK-UHFFFAOYSA-N 0.000 description 1
- WKZLSULWHNTYQH-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-[3-(dimethylamino)propyl]butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)NCCCN(C)C)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 WKZLSULWHNTYQH-UHFFFAOYSA-N 0.000 description 1
- SRQBXGREFBIHPK-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-cyclopentylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NC1CCCC1 SRQBXGREFBIHPK-UHFFFAOYSA-N 0.000 description 1
- YZFGINMRXMWMOP-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-cyclopropyl-n-methylbutanamide Chemical compound N=1C=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C2C=1NC(C=1NC2=CC=C(Cl)C=C2N=1)CCC(=O)N(C)C1CC1 YZFGINMRXMWMOP-UHFFFAOYSA-N 0.000 description 1
- MAUOWUDOVCSFNL-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-cyclopropylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NC1CC1 MAUOWUDOVCSFNL-UHFFFAOYSA-N 0.000 description 1
- OOYLWMKIAIJFHX-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-ethyl-n-(methylcarbamoyl)butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)N(CC)C(=O)NC)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 OOYLWMKIAIJFHX-UHFFFAOYSA-N 0.000 description 1
- MAGBCZBHOVIDJU-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-methyl-n-piperidin-4-ylbutanamide Chemical compound N=1C=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C2C=1NC(C=1NC2=CC(Cl)=CC=C2N=1)CCC(=O)N(C)C1CCNCC1 MAGBCZBHOVIDJU-UHFFFAOYSA-N 0.000 description 1
- SGTBMMKDVSGGJE-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-piperidin-2-ylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NC1CCCCN1 SGTBMMKDVSGGJE-UHFFFAOYSA-N 0.000 description 1
- WQZNLXOLFPLAMV-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-piperidin-4-ylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NC1CCNCC1 WQZNLXOLFPLAMV-UHFFFAOYSA-N 0.000 description 1
- ABKGUPQLWXSSEY-JXFKEZNVSA-N 4-[(2s)-2-(aminomethyl)pyrrolidine-1-carbonyl]-3-chloro-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]benzamide Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Cl)=CC=C1C(=O)N1CCC[C@H]1CN ABKGUPQLWXSSEY-JXFKEZNVSA-N 0.000 description 1
- YMZJXUFDWISWOF-RVQJUJIASA-N 4-[(2s)-2-(aminomethyl)pyrrolidine-1-carbonyl]-3-chloro-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfinylpropyl]benzamide Chemical compound N([C@@H](CCS(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Cl)=CC=C1C(=O)N1CCC[C@H]1CN YMZJXUFDWISWOF-RVQJUJIASA-N 0.000 description 1
- GMJOOPRTIOBJQC-JXFKEZNVSA-N 4-[(2s)-2-(aminomethyl)pyrrolidine-1-carbonyl]-3-chloro-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfonylpropyl]benzamide Chemical compound N([C@@H](CCS(=O)(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1Cl)=CC=C1C(=O)N1CCC[C@H]1CN GMJOOPRTIOBJQC-JXFKEZNVSA-N 0.000 description 1
- SSVFRHRXPVMKDZ-UHFFFAOYSA-N 4-[2-(aminomethyl)pyrrolidine-1-carbonyl]-3-chloro-n-[1-(6-chloro-1h-benzimidazol-2-yl)ethyl]benzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(=O)C(C=C1Cl)=CC=C1C(=O)N1CCCC1CN SSVFRHRXPVMKDZ-UHFFFAOYSA-N 0.000 description 1
- QZOMOTSQDTVSFR-UHFFFAOYSA-N 4-[3-(aminomethyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl]-N-[(5-carbamimidoyl-2-hydroxyphenyl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1=2CCCC=2C(CN)=NN1C(C(=C1)C(F)(F)F)=CC=C1C(=O)NCC1=CC(C(N)=N)=CC=C1O QZOMOTSQDTVSFR-UHFFFAOYSA-N 0.000 description 1
- SIJWTCYOPDQSDX-UHFFFAOYSA-N 4-[4-[1-(6-chloro-1h-benzimidazol-2-yl)ethylamino]-6-methylquinoline-7-carbonyl]piperazin-2-one Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(C1=CC=2C)=CC=NC1=CC=2C(=O)N1CCNC(=O)C1 SIJWTCYOPDQSDX-UHFFFAOYSA-N 0.000 description 1
- GZERKQHTAMDCGI-UHFFFAOYSA-N 4-[4-[[1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]-6-methylquinoline-7-carbonyl]piperazin-2-one Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCSC)NC(C1=CC=2C)=CC=NC1=CC=2C(=O)N1CCNC(=O)C1 GZERKQHTAMDCGI-UHFFFAOYSA-N 0.000 description 1
- FFXMMUQJKCFJLO-GOSISDBHSA-N 4-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-hydroxyethyl]amino]quinazoline-7-carbonyl]piperazin-2-one Chemical compound N([C@H](CO)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCNC(=O)C1 FFXMMUQJKCFJLO-GOSISDBHSA-N 0.000 description 1
- RSGDQMKQVSAEMO-JOCHJYFZSA-N 4-[acetyl(cyclopentyl)amino]-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methylsulfanylethyl]-3-methylbenzamide Chemical compound N([C@H](CSC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C)=CC=C1N(C(C)=O)C1CCCC1 RSGDQMKQVSAEMO-JOCHJYFZSA-N 0.000 description 1
- ZWGRFVIVQYBHJY-UHFFFAOYSA-N 4-hydroxy-3-[2-phenyl-1-[[7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]ethyl]benzenecarboximidamide Chemical compound NC(=N)C1=CC=C(O)C(C(CC=2C=CC=CC=2)NC=2C3=CC=C(C=C3N=CN=2)C(=O)N2CCCC2)=C1 ZWGRFVIVQYBHJY-UHFFFAOYSA-N 0.000 description 1
- IJPMONDQLMWKGE-UHFFFAOYSA-N 4-hydroxy-3-[[[6-methyl-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]benzenecarboximidamide Chemical compound N1=CN=C2C=C(C(=O)N3CCCC3)C(C)=CC2=C1NCC1=CC(C(N)=N)=CC=C1O IJPMONDQLMWKGE-UHFFFAOYSA-N 0.000 description 1
- LEKPHEUTAHOLKA-UHFFFAOYSA-N 4-hydroxy-3-[[[7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]benzenecarboximidamide Chemical compound NC(=N)C1=CC=C(O)C(CNC=2C3=CC=C(C=C3N=CN=2)C(=O)N2CCCC2)=C1 LEKPHEUTAHOLKA-UHFFFAOYSA-N 0.000 description 1
- ZOTPACDGKSMJRN-UHFFFAOYSA-N 4-hydroxy-3-[[[7-methoxy-6-(pyrrolidine-1-carbonyl)isoquinolin-1-yl]amino]methyl]benzenecarboximidamide Chemical compound N1=CC=C2C=C(C(=O)N3CCCC3)C(OC)=CC2=C1NCC1=CC(C(N)=N)=CC=C1O ZOTPACDGKSMJRN-UHFFFAOYSA-N 0.000 description 1
- GPUHJPCLUJUQCD-UHFFFAOYSA-N 8-[4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)N(CC1)CCC21CNC(=O)O2 GPUHJPCLUJUQCD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IXRSTBMSJCSELI-SMSORMJASA-N ClC=1C=C2C(=NC=NC2=CC1C(=O)N1[C@@](CCC1)(C(=O)OC(C)(C)C)CN)N[C@@H](CCS(=O)(=O)C)C1=NC2=C(N1)C=CC(=C2)Cl Chemical compound ClC=1C=C2C(=NC=NC2=CC1C(=O)N1[C@@](CCC1)(C(=O)OC(C)(C)C)CN)N[C@@H](CCS(=O)(=O)C)C1=NC2=C(N1)C=CC(=C2)Cl IXRSTBMSJCSELI-SMSORMJASA-N 0.000 description 1
- DMOFVXGTPDDTCI-SMSORMJASA-N ClC=1C=C2C(=NC=NC2=CC1C(=O)N1[C@@](CCC1)(C(=O)OC(C)(C)C)CN)N[C@@H](CCSC)C1=NC2=C(N1)C=CC(=C2)Cl Chemical compound ClC=1C=C2C(=NC=NC2=CC1C(=O)N1[C@@](CCC1)(C(=O)OC(C)(C)C)CN)N[C@@H](CCSC)C1=NC2=C(N1)C=CC(=C2)Cl DMOFVXGTPDDTCI-SMSORMJASA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KDRBRQMQRZFBKA-UHFFFAOYSA-N N',4-dihydroxy-3-[[[6-methyl-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]benzenecarboximidamide Chemical compound N1=CN=C2C=C(C(=O)N3CCCC3)C(C)=CC2=C1NCC1=CC(C(=N)NO)=CC=C1O KDRBRQMQRZFBKA-UHFFFAOYSA-N 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- KOBZYVWAIIENIO-UHFFFAOYSA-N N-[1-[(5-carbamimidoyl-2-hydroxyphenyl)methylamino]-7-methylisoquinolin-6-yl]-N-cyclopentylacetamide Chemical compound C=1C2=CC=NC(NCC=3C(=CC=C(C=3)C(N)=N)O)=C2C=C(C)C=1N(C(=O)C)C1CCCC1 KOBZYVWAIIENIO-UHFFFAOYSA-N 0.000 description 1
- IMTCKVSOUDKQSW-UHFFFAOYSA-N N-[amino-[4-hydroxy-3-[[[7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]phenyl]methylidene]benzamide Chemical compound OC1=CC=C(C(=N)NC(=O)C=2C=CC=CC=2)C=C1CNC(C1=CC=2)=NC=NC1=CC=2C(=O)N1CCCC1 IMTCKVSOUDKQSW-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- ZZBSAXFWOZVWOG-OMOCHNIRSA-N [(2r)-2-(aminomethyl)pyrrolidin-1-yl]-[4-[1-(6-chloro-1h-benzimidazol-2-yl)ethylamino]-6-methylquinolin-7-yl]methanone Chemical compound N=1C2=CC=C(Cl)C=C2NC=1C(C)NC(C1=CC=2C)=CC=NC1=CC=2C(=O)N1CCC[C@@H]1CN ZZBSAXFWOZVWOG-OMOCHNIRSA-N 0.000 description 1
- XANBDYJRXBRKPJ-ZUOKHONESA-N [(2r)-2-(aminomethyl)pyrrolidin-1-yl]-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-hydroxyethyl]amino]quinazolin-7-yl]methanone Chemical compound NC[C@H]1CCCN1C(=O)C1=CC2=NC=NC(N[C@H](CO)C=3NC4=CC=C(Cl)C=C4N=3)=C2C=C1Cl XANBDYJRXBRKPJ-ZUOKHONESA-N 0.000 description 1
- XAHSRTFNRQVPDW-QRWLVFNGSA-N [(2r)-2-(aminomethyl)pyrrolidin-1-yl]-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]quinazolin-7-yl]methanone Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCC[C@@H]1CN XAHSRTFNRQVPDW-QRWLVFNGSA-N 0.000 description 1
- CPVNKLWRHQRGFJ-QBYSONFBSA-N [(2r)-2-(aminomethyl)pyrrolidin-1-yl]-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfinylpropyl]amino]quinazolin-7-yl]methanone Chemical compound N([C@@H](CCS(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCC[C@@H]1CN CPVNKLWRHQRGFJ-QBYSONFBSA-N 0.000 description 1
- HPHBHDUSVYOGTD-QRWLVFNGSA-N [(2r)-2-(aminomethyl)pyrrolidin-1-yl]-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfonylpropyl]amino]quinazolin-7-yl]methanone Chemical compound N([C@@H](CCS(=O)(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCC[C@@H]1CN HPHBHDUSVYOGTD-QRWLVFNGSA-N 0.000 description 1
- YLMSXNRSXYNMJV-GXTWGEPZSA-N [(2r)-2-(aminomethyl)pyrrolidin-1-yl]-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]methanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCC[C@@H]1CN YLMSXNRSXYNMJV-GXTWGEPZSA-N 0.000 description 1
- HGNBKXMAULMPKA-BEUBQONESA-N [(2r)-2-[amino(methylsulfonyl)methyl]pyrrolidin-1-yl]-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfonylpropyl]amino]quinazolin-7-yl]methanone Chemical compound N([C@@H](CCS(=O)(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCC[C@@H]1C(N)S(C)(=O)=O HGNBKXMAULMPKA-BEUBQONESA-N 0.000 description 1
- CBRMMAPWXKYFOY-UHFFFAOYSA-N [(Z)-[amino-[4-hydroxy-3-[[[6-methyl-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]phenyl]methylidene]carbamoyl]oxymethyl acetate Chemical compound CC(=O)OCOC(=O)NC(=N)C1=CC=C(O)C(CNC=2C3=CC(C)=C(C(=O)N4CCCC4)C=C3N=CN=2)=C1 CBRMMAPWXKYFOY-UHFFFAOYSA-N 0.000 description 1
- YLMSXNRSXYNMJV-UHFFFAOYSA-N [2-(aminomethyl)pyrrolidin-1-yl]-[6-chloro-4-[1-(6-chloro-1h-benzimidazol-2-yl)ethylamino]quinazolin-7-yl]methanone Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1CN YLMSXNRSXYNMJV-UHFFFAOYSA-N 0.000 description 1
- GWOSHEGHIBUWTR-UHFFFAOYSA-N [4-[1-(6-chloro-1h-benzimidazol-2-yl)ethylamino]-6-methylquinolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(C1=CC=2C)=CC=NC1=CC=2C(=O)N1CCCC1 GWOSHEGHIBUWTR-UHFFFAOYSA-N 0.000 description 1
- ZZHRRQMWVFZPLU-UUSAFJCLSA-N [4-[[(1s)-1-(6-bromo-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]-6-chloroquinazolin-7-yl]-(2,5-dihydro-1h-pyrrol-2-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC(Br)=CC=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)C1NCC=C1 ZZHRRQMWVFZPLU-UUSAFJCLSA-N 0.000 description 1
- OWFUOMYKGDFREB-HXUWFJFHSA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]-6-methoxyquinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2OC)=NC=NC1=CC=2C(=O)N1CC=CC1 OWFUOMYKGDFREB-HXUWFJFHSA-N 0.000 description 1
- WVUUBWGNSHRFJO-HWYAHNCWSA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]-6-methylquinazolin-7-yl]-(1,3-thiazolidin-2-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2C)=NC=NC1=CC=2C(=O)C1NCCS1 WVUUBWGNSHRFJO-HWYAHNCWSA-N 0.000 description 1
- BYOCAOZUUVQFAV-OAQYLSRUSA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]-6-methylquinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2C)=NC=NC1=CC=2C(=O)N1CC=CC1 BYOCAOZUUVQFAV-OAQYLSRUSA-N 0.000 description 1
- QDEWTQJURKBCOQ-IBGZPJMESA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]-6-methoxyquinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound COC1=CC2=C(N[C@@H](CCSC)C=3NC4=CC=C(Cl)C=C4N=3)N=CN=C2C=C1C(=O)N1CC=CC1 QDEWTQJURKBCOQ-IBGZPJMESA-N 0.000 description 1
- NXKZJYBXDNTGTI-FQEVSTJZSA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]-6-methylquinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2C)=NC=NC1=CC=2C(=O)N1CC=CC1 NXKZJYBXDNTGTI-FQEVSTJZSA-N 0.000 description 1
- WVBUFIWRIFMHHI-UHFFFAOYSA-N [4-[[1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]-6-methylquinolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCSC)NC(C1=CC=2C)=CC=NC1=CC=2C(=O)N1CCCC1 WVBUFIWRIFMHHI-UHFFFAOYSA-N 0.000 description 1
- RXMKXQLMQHESMK-UHFFFAOYSA-N [4-[[1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfonylpropyl]amino]-6-methylquinolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound CC1=CC2=C(NC(CCS(C)(=O)=O)C=3NC4=CC=C(Cl)C=C4N=3)C=CN=C2C=C1C(=O)N1CCCC1 RXMKXQLMQHESMK-UHFFFAOYSA-N 0.000 description 1
- YPHYCHLMZNDYID-HXUWFJFHSA-N [6-bromo-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Br)=NC=NC1=CC=2C(=O)N1CC=CC1 YPHYCHLMZNDYID-HXUWFJFHSA-N 0.000 description 1
- IKMZDHWOYWYJTR-LBPRGKRZSA-N [6-bromo-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Br)=NC=NC1=CC=2C(=O)N1CC=CC1 IKMZDHWOYWYJTR-LBPRGKRZSA-N 0.000 description 1
- RFWYAAZYBLYSRF-LJQANCHMSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-hydroxyethyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@H](CO)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 RFWYAAZYBLYSRF-LJQANCHMSA-N 0.000 description 1
- KRFFCDITXHDYGG-ZZWBGTBQSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]quinazolin-7-yl]-(1,3-thiazolidin-2-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)C1NCCS1 KRFFCDITXHDYGG-ZZWBGTBQSA-N 0.000 description 1
- BCFWJMYQBDXGNR-HXUWFJFHSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 BCFWJMYQBDXGNR-HXUWFJFHSA-N 0.000 description 1
- ABXRNOGOFRLAFG-HXUWFJFHSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]quinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 ABXRNOGOFRLAFG-HXUWFJFHSA-N 0.000 description 1
- CGVLJASAIJQWHX-NRFANRHFSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-(1,1-dioxo-1,2-thiazolidin-2-yl)propyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound C([C@@H](C=1NC2=CC=C(C=C2N=1)Cl)NC=1C2=CC(Cl)=C(C(=O)N3CC=CC3)C=C2N=CN=1)CN1CCCS1(=O)=O CGVLJASAIJQWHX-NRFANRHFSA-N 0.000 description 1
- ZNQCCBMUUWWSSS-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methoxypropyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](CCOC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 ZNQCCBMUUWWSSS-IBGZPJMESA-N 0.000 description 1
- YIXULUKTIICPNC-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]quinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 YIXULUKTIICPNC-IBGZPJMESA-N 0.000 description 1
- HAJMCTXDBRVESQ-WUTYVCDSSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfinylpropyl]amino]quinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](CCS(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 HAJMCTXDBRVESQ-WUTYVCDSSA-N 0.000 description 1
- ZBLDZSBGMXPXNY-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfonylpropyl]amino]quinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](CCS(=O)(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 ZBLDZSBGMXPXNY-IBGZPJMESA-N 0.000 description 1
- PULJCUHABQICCL-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)butyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](CCC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 PULJCUHABQICCL-IBGZPJMESA-N 0.000 description 1
- WQUXFWRNMWSHNO-NSHDSACASA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-(1,3-thiazolidin-3-yl)methanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCSC1 WQUXFWRNMWSHNO-NSHDSACASA-N 0.000 description 1
- KRKQMWHVCXTIFN-LBPRGKRZSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 KRKQMWHVCXTIFN-LBPRGKRZSA-N 0.000 description 1
- UGIZUYOZZYUSLI-WMZOPIPTSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-[(2s)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]methanone Chemical compound C([C@@H]1CCCN1C(=O)C=1C=C2N=CN=C(C2=CC=1Cl)N[C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)N1CCCC1 UGIZUYOZZYUSLI-WMZOPIPTSA-N 0.000 description 1
- WLYWOHREUVJHNO-LBPRGKRZSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 WLYWOHREUVJHNO-LBPRGKRZSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- CEMPRUFIGKWFHT-SANMLTNESA-N benzyl (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[3-methyl-4-(pyrrolidine-1-carbonyl)benzoyl]amino]butanoate Chemical compound CC1=CC(C(=O)N[C@@H](CCC(=O)OCC=2C=CC=CC=2)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 CEMPRUFIGKWFHT-SANMLTNESA-N 0.000 description 1
- TVRYMMKZRZBXBH-VWLOTQADSA-N benzyl (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoate Chemical compound C([C@@H](C=1NC2=CC=C(C=C2N=1)Cl)NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CC(=O)OCC1=CC=CC=C1 TVRYMMKZRZBXBH-VWLOTQADSA-N 0.000 description 1
- TVRYMMKZRZBXBH-UHFFFAOYSA-N benzyl 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoate Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)OCC1=CC=CC=C1 TVRYMMKZRZBXBH-UHFFFAOYSA-N 0.000 description 1
- JGFDYOPPLIVQLL-NDEPHWFRSA-N benzyl n-[(5s)-5-(6-chloro-1h-benzimidazol-2-yl)-5-[[3-methyl-4-(pyrrolidine-1-carbonyl)benzoyl]amino]pentyl]carbamate Chemical compound CC1=CC(C(=O)N[C@@H](CCCCNC(=O)OCC=2C=CC=CC=2)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 JGFDYOPPLIVQLL-NDEPHWFRSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003828 danaparoid Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical class C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
- NYFXIFORCJEPCK-FQEVSTJZSA-N ethyl (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(2,5-dihydropyrrole-1-carbonyl)quinazolin-4-yl]amino]butanoate Chemical compound N([C@@H](CCC(=O)OCC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 NYFXIFORCJEPCK-FQEVSTJZSA-N 0.000 description 1
- VXLJQDPUTFXYCN-FQEVSTJZSA-N ethyl (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoate Chemical compound N([C@@H](CCC(=O)OCC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 VXLJQDPUTFXYCN-FQEVSTJZSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- FMSAVQSHZTZMTE-UHFFFAOYSA-N n-(2-aminoethyl)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)NCCN)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 FMSAVQSHZTZMTE-UHFFFAOYSA-N 0.000 description 1
- FYVOJJBMSQFAOF-SFHVURJKSA-N n-[(1r)-1-(6-bromo-1h-benzimidazol-2-yl)-2-hydroxyethyl]-3-chloro-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](CO)C=1NC2=CC=C(Br)C=C2N=1)C(=O)C(C=C1Cl)=CC=C1C(=O)N1CC=CC1 FYVOJJBMSQFAOF-SFHVURJKSA-N 0.000 description 1
- DLEQLZVAWNSMGJ-IBGZPJMESA-N n-[(1r)-1-(6-bromo-1h-benzimidazol-2-yl)-2-hydroxyethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CO)C=2NC3=CC=C(Br)C=C3N=2)=CC=C1C(=O)N1CCCC1 DLEQLZVAWNSMGJ-IBGZPJMESA-N 0.000 description 1
- KQORXQUOVZHIOJ-IBGZPJMESA-N n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-hydroxyethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CO)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 KQORXQUOVZHIOJ-IBGZPJMESA-N 0.000 description 1
- ZEOBBQISYXVYKH-SFHVURJKSA-N n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-hydroxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)-3-(trifluoromethyl)benzamide Chemical compound N([C@@H](CO)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C(F)(F)F)=CC=C1C(=O)N1CC=CC1 ZEOBBQISYXVYKH-SFHVURJKSA-N 0.000 description 1
- FLGOVBBBTRHNGA-IBGZPJMESA-N n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-hydroxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)-3-methylbenzamide Chemical compound CC1=CC(C(=O)N[C@@H](CO)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CC=CC1 FLGOVBBBTRHNGA-IBGZPJMESA-N 0.000 description 1
- NYFNPJJDRQUKJO-FQEVSTJZSA-N n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 NYFNPJJDRQUKJO-FQEVSTJZSA-N 0.000 description 1
- AWGAMXJCLLDCOD-DEOSSOPVSA-N n-[(1s)-1,3-bis(6-chloro-1h-benzimidazol-2-yl)propyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCC=2NC3=CC=C(Cl)C=C3N=2)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 AWGAMXJCLLDCOD-DEOSSOPVSA-N 0.000 description 1
- IMMKWITYEBLIRV-IBGZPJMESA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-(2h-tetrazol-5-yl)propyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCC=2NN=NN=2)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 IMMKWITYEBLIRV-IBGZPJMESA-N 0.000 description 1
- GIQKVPRDYSGSEQ-FQEVSTJZSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-(methanesulfonamido)propyl]-4-(2,5-dihydropyrrole-1-carbonyl)-3-methylbenzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCNS(C)(=O)=O)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CC=CC1 GIQKVPRDYSGSEQ-FQEVSTJZSA-N 0.000 description 1
- IIBIOFPXPWCQOI-FQEVSTJZSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methoxypropyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](CCOC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 IIBIOFPXPWCQOI-FQEVSTJZSA-N 0.000 description 1
- ZJDHCLWEPVKIFP-FQEVSTJZSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 ZJDHCLWEPVKIFP-FQEVSTJZSA-N 0.000 description 1
- IELNPIPUEPYPPR-SQLGYAFXSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfinylpropyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCS(C)=O)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 IELNPIPUEPYPPR-SQLGYAFXSA-N 0.000 description 1
- CREMJYSQFJTZSD-VWLOTQADSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-phenylpropyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCC=2C=CC=CC=2)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 CREMJYSQFJTZSD-VWLOTQADSA-N 0.000 description 1
- JEIHYYUQOHXSSV-VWLOTQADSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-4-(2-methyl-2,6-diazaspiro[3.4]octan-6-yl)-4-oxobutyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound C1N(C)CC21CN(C(=O)CC[C@H](NC(=O)C=1C=C(C)C(C(=O)N3CCCC3)=CC=1)C=1NC3=CC=C(Cl)C=C3N=1)CC2 JEIHYYUQOHXSSV-VWLOTQADSA-N 0.000 description 1
- HOXXPKVCSSRJCX-URXFXBBRSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-4-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-4-oxobutyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCC(=O)N2[C@@H](CCC2)CO)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 HOXXPKVCSSRJCX-URXFXBBRSA-N 0.000 description 1
- MOJCALZXKCDURL-QHCPKHFHSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-4-oxo-4-pyrrolidin-1-ylbutyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCC(=O)N2CCCC2)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 MOJCALZXKCDURL-QHCPKHFHSA-N 0.000 description 1
- MHMWIAUKLJQIKY-FQEVSTJZSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)butyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](CCC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 MHMWIAUKLJQIKY-FQEVSTJZSA-N 0.000 description 1
- ZPAAUQXGKGQYEY-QPPBQGQZSA-N n-[(1s)-4-[(2r)-2-(aminomethyl)pyrrolidin-1-yl]-1-(6-chloro-1h-benzimidazol-2-yl)-4-oxobutyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCC(=O)N2[C@H](CCC2)CN)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 ZPAAUQXGKGQYEY-QPPBQGQZSA-N 0.000 description 1
- ZPAAUQXGKGQYEY-URXFXBBRSA-N n-[(1s)-4-[(2s)-2-(aminomethyl)pyrrolidin-1-yl]-1-(6-chloro-1h-benzimidazol-2-yl)-4-oxobutyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCC(=O)N2[C@@H](CCC2)CN)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 ZPAAUQXGKGQYEY-URXFXBBRSA-N 0.000 description 1
- WNCGGHURWVEGHN-IBGZPJMESA-N n-[(3s)-3-(6-chloro-1h-benzimidazol-2-yl)-3-[[6-chloro-7-(2,5-dihydropyrrole-1-carbonyl)quinazolin-4-yl]amino]propyl]methanesulfonamide Chemical compound N([C@@H](CCNS(=O)(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 WNCGGHURWVEGHN-IBGZPJMESA-N 0.000 description 1
- AQKCVIJGQHMSEJ-UHFFFAOYSA-N n-[1-(6-bromo-1h-benzimidazol-2-yl)ethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N=1C2=CC(Br)=CC=C2NC=1C(C)NC(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 AQKCVIJGQHMSEJ-UHFFFAOYSA-N 0.000 description 1
- NYFNPJJDRQUKJO-UHFFFAOYSA-N n-[1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(COC)NC(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 NYFNPJJDRQUKJO-UHFFFAOYSA-N 0.000 description 1
- NIRFBYFEHNCWDS-UHFFFAOYSA-N n-[1-(6-chloro-1h-benzimidazol-2-yl)-3-methylbutyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CC(C)C)NC(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 NIRFBYFEHNCWDS-UHFFFAOYSA-N 0.000 description 1
- XSXSXHGFTUXHHS-UHFFFAOYSA-N n-[1-(6-chloro-1h-benzimidazol-2-yl)ethyl]-3-ethyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CCC1=CC(C(=O)NC(C)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 XSXSXHGFTUXHHS-UHFFFAOYSA-N 0.000 description 1
- SXZNYIIOWDSYJU-UHFFFAOYSA-N n-[1-(6-chloro-1h-benzimidazol-2-yl)ethyl]-4-(2,5-dihydropyrrole-1-carbonyl)-3-methylbenzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(=O)C(C=C1C)=CC=C1C(=O)N1CC=CC1 SXZNYIIOWDSYJU-UHFFFAOYSA-N 0.000 description 1
- MXSUKUHNZNKHBL-UHFFFAOYSA-N n-[4-bromo-2-[(5-chloropyridin-2-yl)carbamoyl]-6-hydroxyphenyl]-1-propan-2-ylpiperidine-4-carboxamide Chemical compound C1CN(C(C)C)CCC1C(=O)NC1=C(O)C=C(Br)C=C1C(=O)NC1=CC=C(Cl)C=N1 MXSUKUHNZNKHBL-UHFFFAOYSA-N 0.000 description 1
- CVUIHKMGZPCPKV-UHFFFAOYSA-N n-[[1-(6-chloro-1h-benzimidazol-2-yl)cyclohexa-2,4-dien-1-yl]methyl]-4-(2,5-dihydropyrrole-1-carbonyl)-3-methylbenzamide Chemical compound CC1=CC(C(=O)NCC2(C=CC=CC2)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CC=CC1 CVUIHKMGZPCPKV-UHFFFAOYSA-N 0.000 description 1
- VDRVPWCWCAMGPB-UHFFFAOYSA-N n-benzyl-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-methylbutanamide Chemical compound N=1C=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C2C=1NC(C=1NC2=CC(Cl)=CC=C2N=1)CCC(=O)N(C)CC1=CC=CC=C1 VDRVPWCWCAMGPB-UHFFFAOYSA-N 0.000 description 1
- XNCLAXZMCGEFKA-UHFFFAOYSA-N n-benzyl-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NCC1=CC=CC=C1 XNCLAXZMCGEFKA-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- IVYHFJFVBLEKDG-PGUFJCEWSA-N propyl 2-[[(2r)-2-[2-[[4-(n'-benzoylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazol-5-yl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]amino]acetate Chemical compound O=C([C@](C)(NCC(=O)OCCC)C=1C=C2N=C(CNC=3C=CC(=CC=3)C(=N)NC(=O)C=3C=CC=CC=3)N(C)C2=CC=1)N1CCCC1 IVYHFJFVBLEKDG-PGUFJCEWSA-N 0.000 description 1
- 229950010535 razaxaban Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- RDMOQHCBQBXEBZ-CVDCTZTESA-N tert-butyl n-[[(2s)-1-[2-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]carbamoyl]benzoyl]pyrrolidin-2-yl]methyl]carbamate Chemical compound N([C@@H](CCSC)C=1NC2=CC(Cl)=CC=C2N=1)C(=O)C(C=C1Cl)=CC=C1C(=O)N1CCC[C@H]1CNC(=O)OC(C)(C)C RDMOQHCBQBXEBZ-CVDCTZTESA-N 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05006711 | 2005-03-29 | ||
| EP05006711.5 | 2005-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070116936A true KR20070116936A (ko) | 2007-12-11 |
Family
ID=36423564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077024953A Ceased KR20070116936A (ko) | 2005-03-29 | 2006-03-27 | 혈전증의 치료를 위한 신규 약제학적 조성물 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060222640A1 (OSRAM) |
| EP (1) | EP1885354A2 (OSRAM) |
| JP (1) | JP2008534552A (OSRAM) |
| KR (1) | KR20070116936A (OSRAM) |
| CN (1) | CN101151030A (OSRAM) |
| AR (1) | AR056291A1 (OSRAM) |
| AU (1) | AU2006228600A1 (OSRAM) |
| BR (1) | BRPI0608656A2 (OSRAM) |
| CA (1) | CA2602563A1 (OSRAM) |
| CL (1) | CL2010000395A1 (OSRAM) |
| EA (1) | EA015122B1 (OSRAM) |
| IL (1) | IL186267A0 (OSRAM) |
| MX (1) | MX2007010664A (OSRAM) |
| NO (1) | NO20074149L (OSRAM) |
| NZ (1) | NZ562775A (OSRAM) |
| TW (1) | TW200722089A (OSRAM) |
| UA (1) | UA92603C2 (OSRAM) |
| WO (1) | WO2006103206A2 (OSRAM) |
| ZA (1) | ZA200706698B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906894B1 (en) | 2000-07-27 | 2014-12-09 | Thomas N. Thomas | Methods for preventing and treating thrombotic disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| IL159273A0 (en) * | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
| CA2610757A1 (en) * | 2005-06-10 | 2006-12-14 | Transpharma Medical, Ltd. | Patch for transdermal drug delivery |
| EP2043632A2 (en) * | 2006-07-17 | 2009-04-08 | Boehringer Ingelheim International GmbH | New indications for direct thrombin inhibitors |
| US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| DE102006051625A1 (de) | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
| WO2009057112A2 (en) * | 2007-10-29 | 2009-05-07 | Transpharma Medical, Ltd. | Vertical patch drying |
| WO2010013231A2 (en) * | 2008-07-29 | 2010-02-04 | Yeda Research And Development Co. Ltd. | Modulation of coagulation factors and effectors of same for control of transplant organ size |
| EP2323605A4 (en) * | 2008-09-10 | 2014-02-05 | Syneron Medical Ltd | TRANSDERMAL RELEASE OF OLIGOSACCHARIDES |
| TW201031651A (en) * | 2008-11-11 | 2010-09-01 | Boehringer Ingelheim Int | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
| AR074313A1 (es) | 2008-11-11 | 2011-01-05 | Boehringer Ingelheim Int | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit |
| CA2738885A1 (en) * | 2008-11-11 | 2010-05-20 | Boehringer Ingelheim International Gmbh | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
| EP2384196B1 (en) * | 2008-12-30 | 2017-09-13 | Johansson, Pär | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof |
| PL2667878T3 (pl) * | 2011-01-25 | 2016-10-31 | Kompozycje i sposoby transplantacji komórek | |
| CN102250099B (zh) * | 2011-05-16 | 2013-10-16 | 中国药科大学 | 一类非肽类抗凝血酶抑制剂、其制法以及医药用途 |
| EP2806879B1 (en) | 2012-01-25 | 2019-03-06 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| WO2014001220A1 (en) | 2012-06-25 | 2014-01-03 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
| EP2722034B1 (en) * | 2012-10-19 | 2020-09-16 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral pharmaceutical formulations comprising dabigatran |
| EP2722033A1 (en) * | 2012-10-19 | 2014-04-23 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical Compositions of Dabigatran Free Base |
| JP6474394B2 (ja) | 2013-07-05 | 2019-02-27 | ユニベルシテ カトリック ドゥ ルーベン | ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用 |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| CN105250286A (zh) * | 2015-11-13 | 2016-01-20 | 谭惠娟 | 一种抗血栓组合物 |
| CN108236612A (zh) * | 2016-12-27 | 2018-07-03 | 李志忠 | 用于冠脉介入手术中抗凝的组合产品及其用途 |
| WO2020180489A1 (en) * | 2019-03-06 | 2020-09-10 | University Of Rochester | Anticoagulant compositions and uses thereof |
| US11654036B2 (en) | 2020-05-26 | 2023-05-23 | Elixir Medical Corporation | Anticoagulant compounds and methods and devices for their use |
| CN115192691B (zh) * | 2022-08-31 | 2025-03-04 | 晓恩医药包装材料(安庆)有限公司 | 一种阿加曲班注射液及预灌封注射器 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
| NZ286082A (en) * | 1995-03-15 | 1998-09-24 | Behringwerke Ag | Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment |
| FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6414008B1 (en) * | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
| DE19834751A1 (de) * | 1998-08-01 | 2000-02-03 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
| GB9930540D0 (en) * | 1999-12-23 | 2000-02-16 | Rhone Poulenc Rorer Pharma | Chemical compounds |
| GB0014134D0 (en) * | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| US8183206B2 (en) * | 2001-09-14 | 2012-05-22 | Mitsubishi Tanabe Pharma Corporation | Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
| DK1485094T4 (da) * | 2002-03-07 | 2020-06-22 | Boehringer Ingelheim Int | Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte |
| DE10235639A1 (de) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
| BRPI0409796A (pt) * | 2003-04-24 | 2006-05-30 | Boehringer Ingelheim Int | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina |
-
2006
- 2006-03-26 US US11/277,503 patent/US20060222640A1/en not_active Abandoned
- 2006-03-27 MX MX2007010664A patent/MX2007010664A/es not_active Application Discontinuation
- 2006-03-27 CA CA002602563A patent/CA2602563A1/en not_active Abandoned
- 2006-03-27 UA UAA200711762A patent/UA92603C2/ru unknown
- 2006-03-27 KR KR1020077024953A patent/KR20070116936A/ko not_active Ceased
- 2006-03-27 CN CNA2006800108359A patent/CN101151030A/zh active Pending
- 2006-03-27 JP JP2008503489A patent/JP2008534552A/ja active Pending
- 2006-03-27 EP EP06725316A patent/EP1885354A2/en not_active Withdrawn
- 2006-03-27 BR BRPI0608656-0A patent/BRPI0608656A2/pt not_active IP Right Cessation
- 2006-03-27 NZ NZ562775A patent/NZ562775A/en unknown
- 2006-03-27 WO PCT/EP2006/061046 patent/WO2006103206A2/en not_active Ceased
- 2006-03-27 EA EA200701841A patent/EA015122B1/ru not_active IP Right Cessation
- 2006-03-27 AU AU2006228600A patent/AU2006228600A1/en not_active Abandoned
- 2006-03-28 TW TW095110732A patent/TW200722089A/zh unknown
- 2006-03-29 AR ARP060101205A patent/AR056291A1/es unknown
-
2007
- 2007-08-10 NO NO20074149A patent/NO20074149L/no not_active Application Discontinuation
- 2007-08-13 ZA ZA200706698A patent/ZA200706698B/xx unknown
- 2007-09-25 IL IL186267A patent/IL186267A0/en unknown
-
2010
- 2010-03-19 US US12/727,933 patent/US20100184729A1/en not_active Abandoned
- 2010-04-21 CL CL2010000395A patent/CL2010000395A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006103206A3 (en) | 2007-01-11 |
| CN101151030A (zh) | 2008-03-26 |
| US20100184729A1 (en) | 2010-07-22 |
| NO20074149L (no) | 2007-12-11 |
| AR056291A1 (es) | 2007-10-03 |
| US20060222640A1 (en) | 2006-10-05 |
| BRPI0608656A2 (pt) | 2010-01-19 |
| CA2602563A1 (en) | 2006-10-05 |
| IL186267A0 (en) | 2008-01-20 |
| TW200722089A (en) | 2007-06-16 |
| JP2008534552A (ja) | 2008-08-28 |
| NZ562775A (en) | 2011-03-31 |
| MX2007010664A (es) | 2007-12-12 |
| AU2006228600A1 (en) | 2006-10-05 |
| WO2006103206A2 (en) | 2006-10-05 |
| EA200701841A1 (ru) | 2008-02-28 |
| EA015122B1 (ru) | 2011-06-30 |
| EP1885354A2 (en) | 2008-02-13 |
| UA92603C2 (ru) | 2010-11-25 |
| CL2010000395A1 (es) | 2010-08-20 |
| ZA200706698B (en) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20070116936A (ko) | 혈전증의 치료를 위한 신규 약제학적 조성물 | |
| EP3288558B1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| CA3172586C (en) | IMATINIB AEROSOL COMPOUNDS AND RELATED USES | |
| CN103458690B (zh) | 治疗肺动脉高压的组合物和方法 | |
| KR20220148847A (ko) | 다브라페닙, erk 억제제, 및 shp2 억제제를 포함하는 삼중 약학적 조합물 | |
| MX2010012290A (es) | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. | |
| RU2324484C2 (ru) | Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) | |
| TWI741286B (zh) | 治療癌症之方法 | |
| JP2018512403A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 | |
| CN118647379A (zh) | 用于治疗癌症的包含cdk2抑制剂和cdk4抑制剂的方法和给药方案 | |
| KR20200128510A (ko) | 림프성 악성종양을 치료하는 방법 | |
| AU2009272814A1 (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| US20090048173A1 (en) | Use Of Dipyridamole For Treatment Of Resistance To Platelet Inhibitors | |
| US20090075949A1 (en) | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | |
| EP4615869A1 (en) | Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain | |
| EP3900722A1 (en) | Combination of finerenone and pecavaptan for the treatment and/or prevention of cardiovascular and/or renal diseases | |
| JP2023065324A (ja) | 抗特発性肺線維症剤 | |
| HK1119932A (en) | Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis | |
| RU2849370C1 (ru) | Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака | |
| JP2018104412A (ja) | 眼疾患の治療及び／又は予防剤 | |
| CN101711155A (zh) | 用于治疗和预防肺动脉高压的噁唑烷酮 | |
| TW201817420A (zh) | 治療或緩解慢性骨髓性白血病用之醫藥組合物 | |
| HK1144255A (en) | Oxazolidinone for the treatment and prophylaxis of pulmonary hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20071029 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20110325 Comment text: Request for Examination of Application |
|
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20130226 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20130830 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20130226 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |